Market Overview

UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'

Related TKMR
Tekmira Back In Vogue After Recent Ebola Outbreak
Maxim Sees Major Upside In These Biotech Stocks
The Vetr community has upgraded $TKMR to 4.5-Stars. (Vetr)

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares are trading seven percent higher Monday after Leerink revealed a $25 price target and Outperform rating.

The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”

TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.

Related Link: Deutsche Bank Raises Achillion Price Target 138%

Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.

The issue was last trading hands at $19.30, a 6.75 percent gain.

Latest Ratings for TKMR

Nov 2014Stifel NicolausMaintainsBuy
Oct 2014Leerink SwannDowngradesOutperformMarket Perform
Aug 2014Leerink PartnersInitiates Coverage onOutperform

View More Analyst Ratings for TKMR
View the Latest Analyst Ratings

Posted-In: Ebola Leerink Michael SchmidtAnalyst Color Price Target Initiation Analyst Ratings


Related Articles (TKMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters